-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Dravet syndrome is a rare childhood inherited epilepsy syndrome characterized by refractic epilepsy and neurodevelopmental problems that occur from inflamed.
70%-80% of DS patients detected mutations in the voltage gated sodium ion channel alpha-1 sub-gene (SCN1A).
characteristic of the syndrome is the drug-refraptic seizures, the overall efficacy of anti-epileptic drug treatment is limited.
nevertheless, the triggers of seizures should be avoided as much as possible and the ongoing state of seizures and seizures should be controlled to the maximum extent possible.
treatment is still the main treatment, some patients can also choose ketogenic diet and neuroconstransic.
biopharmaceutical company, Epigenix Therapeutics, recently announced that it has launched a multi-center, randomized, double-blind, placebo-controlled concept validation trial for EPX-100 to treat children with Dravet syndrome.
phase II study will confirm the efficacy and safety of EPX-100 in children with Dravet syndrome.
is currently working with international CRO company GreenLight Clinical to recruit patients.
- Jun Lee, President and CEO of Epygenix Therapeutics, said, "We are very excited about the launch of the EPX-100 Phase II study, which is a milestone for the company as it moves to the next phase."
.
